|
Poster Discussion The authors are requested to be available for discussion at their posters on Saturday, May 15, 2004 (2. Obergeschoss)
11:45 – 13:30 Poster Session I
Vorsitz/Chair: T. Glück, R. Wagner, Regensburg
Herpes Virus Infections: Poster 11 – Poster 16
Diagnostic Tests: Poster 21 – Poster 23
HIV and Other Retrovirus Infections: Poster 30 – Poster 60
11:45 – 13:15 Poster Session II
Vorsitz/Chair: G. Fätkenheuer, U. Wieland, Köln
Respiratory Virus Infections: Poster 1 – Poster 4
Viral Hepatitis: Poster 61 – Poster 70
Case Reports and Miscellaneous: Poster 81 – Poster 95
Respiratory Virus Infections
(1) Detection of respiratory syncytial virus and human metapneumovirus
by RT-PCR and real-time PCR
Moya-Suri V, Bruns R, Zimmermann K, Mentel R, Gürtler L
(2) Monitoring the kinetics of a vaccine-induced T-cell response after influenza vaccination
Sester M, Gärtner BC, Kuhlmann MK, Sester U, Köhler H
(3) Characterization of human metapneumoviruses isolated during the winter season 2002/2003 in Germany
Huck B, Sasmaz G, Krempl C, Puppe W, Neumann-Haefelin D, Ari S,
Walther S, Weigl J, Falcone V
(4) Influenza vaccination among physicians is associated with better knowledge and lower anticipation of
side effects
Ehrenstein B, Bitter S, Glck T, Salzberger B
Herpes Virus Infections
(11) Is the combined analysis of HHV-8 specific humoral and cellular immune responses as a more accurate
measure to assign the individual HHV-8 status?
Gärtner BC, Lönard B, Sester U, Mueller-Lantzsch N, Pees H, Sester W,
Köhler H
(12) Implications for pathogenesis: post-translational control of Epstein-Barr virus lytic cycle gene
BZLF1 is hampered by mutations in a strain isolated from a case of chronic active infection
Jäger M, Knig U, Niller HH, Larcher C, Huemer H, Mitterer M, Wolf H,
Schwarzmann F
(13) Fast emergence of ganciclovir-resistant cytomegalovirus in solid organ transplant-recipients:
advantage of UL97 genotyping versus phenotyping for therapy monitoring
Michel D, Mertens Th
(14) Human herpesvirus type 8 in HIV-infected patients with interstitial pneumonitis
Mller A, Klussmann P, Ftkenheuer G, Salzberger B, Franzen C
(15) Avidity determination of cytomegalovirus immunoglobulin G antibodies by a recombinant immunoblot
Jauris C, Herre U, Schubert J, Arnim B v, Weissbrich B
(16) Detection of herpesvirus DNA in cerebrospinal fluid by real time PCR and correlation with clinical
symptoms
Plentz A, Jilg W, Kochanowski B, Ibach B, Drobnik-Dorner A, Knll A
Diagnostic Tests
(21) Rapid laboratory diagnosis in an outbreak of Ebola haemorrhagic fever, Rep. of Congo 2003
Lucht A, Mller P, Becker S, Grunow R, Götz M, Feldmann H, Campbell
P, Wittmann T, Catherine C, Bataboukila P, Yaba P, Formenty P
(22) The EU Invitro Diagnostic Directive, a weapon of mass destruction
Tedder RS
(23) Induction of MHC class-I and -II restricted epitope presentation by urea-adjuvated BZLF1 protein: a
novel technology for the detection of protein-specific cytotoxic T-cells
Barabas S, Bauer T, Bauer B, Pllmann K, Wagner R, Jilg W, Wolf H, Deml L
HIV and Other Retrovirus Infections
(30) Vaccination status and practice of vaccination recommendations in the Regensburg HIV cohort
Schneidewind A, Audebert F, Kstler J, Glck T, Salzberger B
(31) Radiology of pulmonary manifestations in patients with HIV infection at the time of highly active
antiretroviral therapy (HAART)
Schmidt GP, Becker-Gaab C, Bogner JR, Sing A, Reiser MF
(32) Analysis of reverse transcriptase activity in infected and noninfected cell culture supernatants and
plasma
Uhlenhaut C, Pauli G, Ellerbrok H
(33) Vigorous HIV specific CD8 T cell responses in late stage HIV infection
Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel A, Rathod A, Addo
MM, Walker BD
(34) Progressive multifokale Leukoenzephalopathie bei AIDS unter Cidofovir
Reichelt D, Grneberg U, Heese C, Akova-tztrk E, Evers S, Husstedt IW
(35) Plasma viral load and CD4+ predict mortality in HIV-2 infected patients and should
be used to guide treatment
Hansmann A, Schim van der Loeff M, Kaye S, Aveika A, Whittle H
(36) Multicentric Castleman’s disease in HIV-infected patients: a clinical and histopathological analysis
of 10 cases
Schmid H, Zietz C, Ihrler S, Goebel FD, Bogner JR
(37) The long-term influence of intra- and/or peripartal antiretroviral prophylaxis on HIV-exposed not
HIV-infected children
Engelhorn C, Strotmann G, Buchholz B, Dunsch D, Neubert J, Vetsi Th,
Notheis G, Belohradsky BH, Wintergerst U
(38) Requests to a HIV drug-drug interaction hotline do not focusing on antiretroviral drugs but on
problems concerning co-medication
Meemken L, Lorenzen T, Graefe K, Meyer P, v. Krosigk A, Stoehr A, Plettenberg A
(39) The detection of HIV viral load comparing the Roche Cobas Amplicor and Roche Cobas TaqMan™
Analyzer
Hower M, Lebert R, Mros K, Schlottmann R, Alp S, Banasch M, Hochdorfer
B, Brockmeyer N, Baier JE, Schmidt WE
(40) Use of tenofovir DF (TDF) in salvage patients following structured treatment interruptions
Ulmer A, Mueller M, Frietsch F
(41) Alterations of haematological parameters in HIV-1 infected persons after initiation of highly active
antiretroviral therapy (HAART)
Wyen C, Schmeisser N, Lehmann C, Ftkenheuer G
(42) Epidemiology and prognosis of severe end-organ CMV-disease in the HAART and pre-HAART eras
Hartmann P, Fatkenheuer G, Wohrmann A, Uyanek B, Salzberger B
(43) Amino acid changes in the HIV-1/gp41 HR1 region associated with ongoing viral replication selected by
T-20 (enfuvirtide) therapy
Eberle J, Goebel FD, Postel N, Jger H, Wienecke R, Bogner JR
(44) Development of drug resistance in intermittent antiretroviral therapy and
mother-to-child-transmission (MTCT) prevention in Southern India
Plentz A, Eberle J, Jacob M, Salzberger B, Jilg W, Samuel NM
(45) HPLC detection method for the analysis of uridine in human serum in HIV patients under HAART
Zilly M, Langmann P, Winzer R, Benesic A, Schirmer D, Walker UA, Klinker H
(46) Immunogenicity and safety of a MVA-BN-Nef vaccine in HIV-1 negative volunteers
Harrer T, Schmitt-Haendle M, Chaplin P, Petzold B, Bergmann S,
Hamacher M, Eismann K, Spriewald B, Kalden JR, Willbold D, Harrer E
(47) Analysis of Nef-specific T-cells, viral rebound and autologous viral sequences during structured
treatment interruption after therapeutic vaccination with a MVA-BN-Nef vaccine in HIV-1 infected patients
Harrer T, Bauerle M, Ferstl B, Chaplin P, Petzold B, Bergmann S,
Hamacher M, Eismann K, Spriewald B, Kalden JR, Harrer E
(48) Immunogenicity studies of GMP grade HIV-1 clade C CN54 DNA candidate vaccines for human phase I
trials in a Balb/c mouse model
Wild J, Bieler K, Deml L, Notka F, Wolf H, Wagner R
(49) The effect of low virus dose exposure on HIV-1 vaccine efficacy in rhesus macaques
Bieler K, Kstler J, Mooij P, Knoop C, Nieuwenhuis I, Bogers W, ten Haaft P, Niphuis H, Koornstra W, Doms R,
Fiorelli V, Cafaro A, Ensoli B, Heeney J, Wagner R
(50) Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles: a potent activator of
innate and acquired immune responses
Deml L, Wild J, Speth C, Dierich M, Wolf H, Wagner R
(51) Enhanced expression of gp120/C3d fusion proteins as a basis for induction of high affinity, broadly
cross neutralizing HIV-specific antibodies
Wanninger V, Bieler K, Notka F, Graf M, Wild J, Jeffs S, Wagner R
(52) Recombinant chemokines as natural adjuvant of innovative HIVvaccines
Bauer A, Notka F, Graf M, Wild J, Wagner R
(53) Intranasal immunization with a recombinant equine herpesvirus (EHV) type induces HIV-1 Gag specific
humoral and cell mediated immune responses
Hofmann H, Köstler J, Wild J, v. Einem J, Trapp S, Osterrieder N, Wagner R
(54) Significant decrease of serum lactate levels after switch to tenofovir
Claas GJ, Bogner JR, Goebel FD
(55) Plasma lactate kinetics after switch from stavudine to tenofovir
Ondrejka S, Bauer AM, Bogner JR
Viral Hepatitis
(61) Hepatitis B reactivation during immunosuppressive therapy for haematopoietic stem cell and solid
organ transplantation: a prospective study of 37 patients with presumably resolved HBV infection
Knöll A, Kreuzpaintner B, Kreuzpaintner E, Jilg W
(62) Seroepidemiology of GB virus-C/hepatitis G, hepatitis B and hepatitis C virus infection in
intravenous drug users in southern Bavaria
Wächtler M, Peterreins K, Backmund M, Hofmann A, Nitschko H, Schraut W, Frösner G
(63) Immune response after hepatitis A vaccination; results of the European VAQTQ(R) Recall
Jaeger G, Campe H, Nitschko H, Kuter B, Harzer E, Koszinowski U
(64) Hepatitis B vaccination of infants born to HIV-infected mothers
Feiterna-Sperling C, Casteleyn S, Kleinkauf N, Grosch-Wrner I
(65) Genotypic and epidemiologic characteristics of hepatitis C virus infection among intravenous drug
addicts in southern Bavaria
Wchtler M, Quadflieg C, Backmund M, Roggendorf M, Ross S
(66) Iron regulates hepatitis C virus translation via stimulation of eIF3 expression
Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, Weiss G
(67) Pegylated interferon alpha 2b (PEG INF) plus ribavirin (RBV) for treatment of chronic hepatitis C in
HIV-coinfected patients in a German multicenter trial
Voigt E, Schulz C, Mauss S, Klausen G, Goelz J, Schranz D, Mosthaf FA, Rockstroh JK
(68) In vitro replication of a lamivudine-resistant hepatitis B virus isolate with mutations within the
core-promoter region
Boehm S, Tausch UC, Roehrl E, Thasler WE, Schlitt HJ, Weiss T, Jilg W
(69) Immune responses induced by a novel adjuvanted hepatitis B vaccine in individuals who underwent liver
transplantation
Bauer T, Deml L, Guenther M, Bienzle U, Jilg W
(70) Regulated and liver specific expression of IFNgamma blocks hepatitis B virus replication
Dumortier J, Oberwinkler H, Schönig K, Bujard H, Giese T, Protzer U
Case Reports and Miscellaneous
(81) 2 years of experience – training course: management of patients with highly contagious diseases
Steffen T
(82) Impact of parvovirus B19 infection in immunocompromised patients: case report and screening of blood
and blood products for parvoviral DNA
Plentz A, Hahn J, Holler E, Knöll A, Jilg W, Modrow S
(83) Quantification of lytic viral mRNAs for monitoring of Epstein-Barr virus (EBV) reactivation in
patients after bone-marrow or renal transplantation
Bauer B, Plentz A, Jilg W
(84) Evaluation of a rapid in vitro assay for the direct and qualitative detection of adenovirus in
conjunctival swabs Truchsess I, Scheibenzuber M, Schtzl HM
(85) Detection of polyomavirus BK and JC in children with kidney diseases and after renal transplantation
Mller A, Beck B, Theilemann K, Michalk D, Franzen C, Hoppe B
(86) Epidemiologic studies of prevalence and characterization of TT-virus in different tissues of the
birth canal
Egerer R, Langner R, Zell R, Seewald H-J, Stelzner A
(87) A janitor with fever and a macular-papular rash after an insect bite
Presterl E, Stoiser B, Guber S, Graninger W
(88) Unusual primary EBV infection in a 73-year-old woman
Prebeck S, Wopfner F, Seebach J, Mhlau M, Schtzl HM
(89) Epidemiology and clinical aspects of hantavirus infections in Underfranconia
Tollmann F, Schubert J, Weissbrich B
(90) A case of benign recurrent aseptic meningitis
Kandel K, Seiberl G, Pichler H
(91) Detection of vaccinia-specific antibodies in the German population
Obermeier M, Nitschko H, Chaplin P, Mateo L, Jäger G
(92) Novel prophylactic and therapeutic approaches against prion
infections
Gilch S, Ertmer A, Wopfner F, Schätzl HM
(93) Towards vaccination approaches against prion infections
Wopfner F, Schulz G, Gilch S, Schätzl HM
(94) The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells
Ertmer A, Gilch S, Yun S-W, Flechsig E, Klebl B, Stein-Gerlach M,
Klein MA, Schätzl HM
(95) Prion diseases: from molecular biology to intervention strategies
Nunziante M, Gilch S, Schätzl HM
|
